Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Asenapine versus other atypical antipsychotics for schizophrenia

Información

DOI:
https://doi.org/10.1002/14651858.CD008902Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 08 diciembre 2010see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esquizofrenia

Copyright:
  1. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Adrian Preda

    Correspondencia a: UC Irvine School of Medicine, UCI Neuropsychiatric Center, Orange, USA

    [email protected]

  • Lawrence Faziola

    University of California at Irvine, Orange, USA

Contributions of authors

AP: writing of protocol.
LF: writing of protocol.

Sources of support

Internal sources

  • None, USA.

    There were no financial resources allocated to this project.

External sources

  • None, USA.

    None

Declarations of interest

None known.

LRF holds less than 1000 common stock equity shares in each of Bristol‐Myers Squibb, USA; Johnson & Johnson, USA; Abbott Labs, USA; and Amgen, USA; companies that may manufacture psychotherapeutics.

Acknowledgements

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods sections of their reviews. We have used this text as the basis of what appears here and adapted it as required.

Version history

Published

Title

Stage

Authors

Version

2010 Dec 08

Asenapine versus other atypical antipsychotics for schizophrenia

Protocol

Adrian Preda, Lawrence Faziola

https://doi.org/10.1002/14651858.CD008902